Evaluation of the Relationship Between Serum Bdnf Concentration and Indicators of Oxidative Stress and Inflammation in Covid-19 Patients With Neurological Disorders - a Pilot Study Publisher Pubmed



Bavarsad K^{1, 2} ; Shalil Ahmadi D³ ; Momeni M⁴ ; Yadyad MJ⁵ ; Salehi Kahyesh R⁶ ; Moradzadegan H⁷ ; Ghafouri S^{1, 2}
Source: Neurological Research Published:2023

Abstract

Introduction: The aim of this study was to determine the effect of serum level of brain-derived neurotrophic factor (BDNF) on the development of neurological disorders in COVID-19 patients and the probable role of oxidative stress and inflammation in this phenomenon. Methods: The present case-control study included 42 COVID-19 patients referring to Golestan and Sina hospitals of Ahvaz, Iran, for treatment. Patients with (n = 18) and without (n = 24) neurological disorders were allocated into test and control groups, respectively. Following blood sampling, serum isolation was done, and the serum was stored at −80°C until biochemical assessment for measuring BDNF, oxidative stress indices, and inflammatory factors. Results: Although no significant brain damage was observed in the COVID-19 patients with neurological disorders, the results showed that the serum level of BDNF in the test group increased compared to that in the control group, and this increment was accompanied with increased Tumor Necrosis Factor-alpha (TNF-α) and decreased Interferon gamma (IFN-γ) levels in the serum. Moreover, compared to the control group, patients in the test group had a decreased level of Thiol and an increased level of Malondialdehyde (MDA) in the serum. Furthermore, there was a significant positive correlation between the serum concentration of BDNF and nitric oxide (NO) in the test group. Conclusion: Using over-the-counter (OTC) medicines which include thiol-group-related agents or any other antioxidants can alleviate oxidative stress and the associated increased inflammation in COVID-19 patients with neurological symptoms. © 2023 Informa UK Limited, trading as Taylor & Francis Group.